Eris Lifesciences share price
NSE: ERISBSE: 540596Pharmaceuticals & BiotechnologySmall Cap
Eris Lifesciences Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jun 2017 · Issue price ₹603
Last close ₹1,156.40down ₹7.20 (0.62%)BSE ₹1,159.60
Share price at the NSE close on 30 Oct 2026. Previous close ₹1,163.60.
30 Oct: open ₹1,163.00, high ₹1,174.70, low ₹1,148.00
52-week range of traded prices to 30 Oct 2026
₹1,069.00Low, 26 Oct 2026₹1,740.00High, 9 Dec 2025
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹16,044 Cr353rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 22.67
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 3.87
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.62%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 19.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 13.4%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.58
- Volume, NSEVolume. Shares traded on the last trading day. Volume in the glossary
- 31,213
About Eris Lifesciences
Eris Lifesciences makes and markets branded prescription medicines in India, centred on specialty therapies such as diabetes, heart disease and dermatology.12 In India its brands are prescribed by specialist doctors such as diabetologists, cardiologists and dermatologists, and it sells through wholesale distributors, stockists, retail pharmacies and e-commerce channels.34 Through its subsidiary Swiss Parenterals it also makes sterile injectables for markets outside India and for contract manufacturing partners.56
Eris ranks among the top 20 companies in the Indian pharmaceutical market.2 Its brands include the diabetes medicines Glimisave, Cyblex and Tendia, the insulins Xsulin, Xglar, Basalog and Insugen, the semaglutide injection Sundae and the heart medicine Eritel.789 It runs 6 manufacturing units in India: 1 of Eris Therapeutics and 2 of Swiss Parenterals in Ahmedabad, and 1 each in Guwahati and in Raisen, Madhya Pradesh.510 Another, in Chennai, belongs to Levim Lifetech, a joint venture in which Eris holds 30%.1112
It was incorporated in 2007, has its registered office in Ahmedabad and is listed on the National Stock Exchange of India and BSE.1 It entered dermatology by acquiring Oaknet Healthcare in 2022, bought Biocon Biologics' Indian branded formulations business, including insulin, oncology and critical care products, effective 1 Apr 2024, and took over the Bhopal plant now called Eris BioNxt in Oct 2024.131415
Its promoters held 54.74% of the shares on 30 Sep 2026, and Amit Bakshi, on the board since inception, is chairman and managing director.1617
Eris Lifesciences key points
Results
- In the quarter to Sep 2026, consolidated revenue rose 12.6% to ₹892 crore and EBITDA (earnings before interest, tax, depreciation and amortisation) rose 7.3% to ₹309 crore, a 34.7% margin.18
- Consolidated profit after tax for the quarter to Sep 2026 rose 39.2% to ₹187 crore; adjusted profit after tax, as the company presents it, rose 17.5% to ₹158 crore.19
- In the year to Mar 2026, consolidated revenue rose 8% to ₹3,129 crore and EBITDA 10% to ₹1,120 crore, a margin of 35.8% against 35.2% a year earlier.20
- Consolidated profit after tax for the year to Mar 2026 was ₹648 crore, including a one-off ₹150 crore deferred tax gain; profit after tax from operations rose 34% to ₹498 crore.21
Market position
- In diabetes care, Eris ranks 5th by revenue and 6th by prescriptions as of Mar 2026, in a market it values at about ₹19,000 crore.22
- By Mar 2026, Eris held 25% of the regular human insulin (RHI) cartridge market and 16% of the combined RHI and glargine (a long-acting insulin) market.23
- In the first quarter after semaglutide lost patent exclusivity in March 2026, Eris ranked 1st by sales volume and 2nd by sales value in the GLP-1 (a class of diabetes drugs) injectable segment.24
- In dermatology, Eris ranks 5th by revenue, with a market share of about 5%, and 3rd by prescriptions among dermatologists.25
Business segments
- Domestic branded formulations. Domestic branded formulations (branded medicines sold in India) revenue rose 14.1% to ₹809 crore in the quarter to Sep 2026 at a 35.7% EBITDA margin, and 11% to ₹2,778 crore in the year to Mar 2026.2627
- International business (Swiss Parenterals). Swiss Parenterals revenue rose 7% to ₹348 crore in the year to Mar 2026, and its segment EBITDA was ₹110 crore, a 32% margin.28
- Eris has licensed its injectables and part of its acute (short-course) portfolio to Zorvia Healthcare, keeping brand ownership and earning a 7% royalty.29
- Share of revenue by therapy area303132
Item year to Mar 2026 Diabetes care 33% Cardiac care 16% Dermatology 13%
Plants and capacity
- The Bhopal plant, Eris BioNxt, has capacity for 25 million insulin vials and 30 million cartridges a year, with 108 million and 45 million to be added in the quarter to Dec 2026; its latest presentation says both are in production.3334
- Ahmedabad campus installed capacity, million units a year on a single shift35
Item year to Mar 2026 Tablets 1,080 Capsules 120 Ointment 25 Injectables 18 Oral liquids 9
Research and development
- Eris has approval to run phase 1 and phase 3 trials of a recombinant semaglutide, with both the drug substance (the active ingredient) and the finished product from its own R&D and manufacturing.36
- Through Levim Lifetech, Eris is developing biologics (medicines made from living cells) including teriparatide, romiplostim, degludec, a degludec-liraglutide combination and recombinant semaglutide.37
Expansion and capital spending
- The company stated in its annual report for the year to Mar 2026 that capital spending of about ₹297 crore that year is part of a ₹750 to 800 crore investment plan over the years to Mar 2026 to Mar 2028.38
- In the year to Mar 2026 Eris brought forward about ₹400 crore of investment, including over ₹150 crore for the Bhopal plant, ₹135 crore for a third injectables unit and ₹100 crore for Levim.3940
- The company stated in its annual report for the year to Mar 2026 that Unit-3, an injectables plant at Swiss Parenterals, is targeted to start commercial production in the year to Mar 2028.41
What the company expects
- In its presentation of 26 Oct 2026, the company said it expects about 100 basis points (hundredths of a percentage point) of domestic branded formulations gross margin (revenue less cost of goods) gain each from the Zorvia licensing and the Bhopal plant.42
- The company stated in its annual report for the year to Mar 2026 that it aims for a ₹1,000 crore international business by the year to Mar 2030.43
- The company stated in its annual report for the year to Mar 2026 that its medium-term objective is a 25% share of the RHI and glargine insulin market.44
Recent events
- On 20 Apr 2026, Eris said HALMED, Croatia's medicines agency, found procedural non-compliances at 2 Swiss Parenterals units, delaying its EU contract manufacturing pipeline with minimal impact on existing business. On 26 Oct 2026 it said corrective actions were on track, with no opportunities cancelled.454647
- On 31 Mar 2026, Eris completed its ₹50 crore purchase of the branded probiotics business of Velbiom Probiotics.4849
- Approved by a board committee on 16 Jan 2026, Eris's purchase of the remaining 30% of Swiss Parenterals from Naishadh Shah, for 23,06,372 new shares valued at ₹423.33 crore, made it wholly owned in January 2026.5051
Last updated
All 51 sources, each with its page
- 1. Annual report, 2 Sep 2026, page 223
- 2. Annual report, 2 Sep 2026, page 18
- 3. Annual report, 2 Sep 2026, page 66
- 4. Annual report, 2 Sep 2026, page 143
- 5. Annual report, 2 Sep 2026, page 18
- 6. Annual report, 2 Sep 2026, page 21
- 7. Annual report, 2 Sep 2026, page 37
- 8. Annual report, 2 Sep 2026, page 36
- 9. Annual report, 2 Sep 2026, page 38
- 10. Annual report, 2 Sep 2026, page 20
- 11. Annual report, 2 Sep 2026, page 20
- 12. Annual report, 2 Sep 2026, page 310
- 13. Annual report, 2 Sep 2026, page 39
- 14. Annual report, 2 Sep 2026, page 256
- 15. Annual report, 2 Sep 2026, page 9
- 16. Investor presentation, 26 Oct 2026, page 15
- 17. Annual report, 2 Sep 2026, page 69
- 18. Investor presentation, 26 Oct 2026, page 13
- 19. Investor presentation, 26 Oct 2026, page 13
- 20. Annual report, 2 Sep 2026, page 16
- 21. Annual report, 2 Sep 2026, page 16
- 22. Annual report, 2 Sep 2026, page 36
- 23. Annual report, 2 Sep 2026, page 12
- 24. Annual report, 2 Sep 2026, page 12
- 25. Annual report, 2 Sep 2026, page 39
- 26. Investor presentation, 26 Oct 2026, page 9
- 27. Annual report, 2 Sep 2026, page 16
- 28. Annual report, 2 Sep 2026, page 16
- 29. Investor presentation, 26 Oct 2026, page 5
- 30. Annual report, 2 Sep 2026, page 36
- 31. Annual report, 2 Sep 2026, page 38
- 32. Annual report, 2 Sep 2026, page 39
- 33. Annual report, 2 Sep 2026, page 9
- 34. Investor presentation, 26 Oct 2026, page 6
- 35. Annual report, 2 Sep 2026, page 21
- 36. Investor presentation, 26 Oct 2026, page 8
- 37. Annual report, 2 Sep 2026, page 14
- 38. Annual report, 2 Sep 2026, page 16
- 39. Annual report, 2 Sep 2026, page 14
- 40. Annual report, 2 Sep 2026, page 22
- 41. Annual report, 2 Sep 2026, page 49
- 42. Investor presentation, 26 Oct 2026, page 6
- 43. Annual report, 2 Sep 2026, page 49
- 44. Annual report, 2 Sep 2026, page 12
- 45. Exchange filing, 20 Apr 2026, page 1
- 46. Exchange filing, 20 Apr 2026, page 2
- 47. Investor presentation, 26 Oct 2026, page 11
- 48. Exchange filing, 31 Mar 2026, page 1
- 49. Annual report, 2 Sep 2026, page 257
- 50. Annual report, 2 Sep 2026, page 257
- 51. Annual report, 2 Sep 2026, page 21
Results
Consolidated; ₹ crore.Eris Lifesciences quarterly results
- Revenue growth, 12 monthsRevenue growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +11.1%
- Net profit growth, 12 monthsNet profit growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +70.2%
Quarter to Sep 2026, against the quarter before
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹892 Crup 2.19%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent. Net profit in the glossary
- ₹187 Crup 30.57%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 21.0%
Revenue by quarter
Peak revenue ₹892 Cr, quarter to Sep 2026; lowest ₹705 Cr, quarter to Mar 2025
Net profit by quarter, a loss in red
| ₹ crore | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 727 | 705 | 773 | 792 | 807 | 757 | 873 | 892 |
| Net profit | 87 | 102 | 125 | 134 | 109 | 279 | 143 | 187 |
| Net margin | 12.0% | 14.5% | 16.2% | 17.0% | 13.5% | 36.9% | 16.4% | 21.0% |
Consolidated. The last eight quarters. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Year to Mar 2026, against the year before
- RevenueRevenue. The pill is the change in revenue against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹3,129 Crup 8.15%
- Net profitNet profit. The pill is the change in net profit against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹648 Crup 72.82%
- Net margin
- 20.7%
Revenue by year
Peak revenue ₹3,129 Cr, year to Mar 2026; lowest ₹856 Cr, year to Mar 2018
Net profit by year, a loss in red
| ₹ crore | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 856 | 982 | 1,074 | 1,212 | 1,347 | 1,685 | 2,009 | 2,894 | 3,129 |
| Net profit | 295 | 291 | 297 | 355 | 406 | 374 | 397 | 375 | 648 |
| Net margin | 34.5% | 29.6% | 27.6% | 29.3% | 30.1% | 22.2% | 19.8% | 12.9% | 20.7% |
Consolidated. Years to March. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Business segments
In the year to Mar 2026 the company reports one business segment, Pharmaceuticals, which carries all its revenue.
Valuation
Today, against the company's own history.Eris Lifesciences PE ratio and valuation
Price to earnings
At or below today's level on 21% of 2,082 trading days since Jun 2018.
LowestHighest
Its median28.29Industry median27.77
Price to book
At or below today's level on 1% of 1,979 trading days since Nov 2018.
LowestHighest
Its median5.45Industry median2.88
Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.
At or below today's level on 66% of 2,296 trading days since Jul 2017.
LowestHighest
Its median0.43%Industry median0.48%
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −7.9% | +75.4% | −47.8% | 0.6% |
| 3 years | +31.7% | +17.3% | +12.0% | 0.4% |
| 5 years | +17.1% | +11.6% | +4.4% | 0.6% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add.
Mutual fund holdings
60 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 11 of the 17 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future. 1 more fund filed its first portfolio on record, holding it.All 60 funds holding Eris Lifesciences
- Bought for the first timeBought for the first time. Funds that held it at the month's end and had not held it in any month on record before.
- 1
- AddedAdded. Funds that held more shares than at the end of the month before.
- 5
- CutCut. Funds that held fewer shares than at the end of the month before.
- 12
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 41
- Sold outSold out. Funds that held it at the end of the month before and hold none at this month's end. Sold out in the glossary
- 34
| Fund | |||
|---|---|---|---|
 HDFC Small Cap FundHDFC Mutual Fund | 64,64,629 | 1.89% | ₹770.5 Cr |
| HDFC Aggressive Hybrid FundHDFC Mutual Fund | 24,59,629 | 1.39% | ₹293.2 Cr |
 Franklin India Small Cap FundFranklin Templeton Mutual Fund | 23,92,469 | 2.00% | ₹285.2 Cr |
| Franklin India Flexi Cap FundFranklin Templeton Mutual Fund | 14,17,881 | 0.93% | ₹169.0 Cr |
 DSP Small Cap FundDSP Mutual Fund | 12,30,000 | 0.68% | ₹146.6 Cr |
 HSBC Small Cap FundHSBC Mutual Fund | 7,76,897 | 0.50% | ₹92.6 Cr |
 UTI Flexi Cap FundUTI Mutual Fund | 7,21,077 | 0.38% | ₹85.9 Cr |
 Mirae Asset Healthcare FundMirae Asset Mutual Fund | 6,99,590 | 2.39% | ₹83.4 Cr |
| HDFC Multi Cap FundHDFC Mutual Fund | 6,78,362 | 0.41% | ₹80.9 Cr |
| HDFC Large & Mid Cap FundHDFC Mutual Fund | 6,75,000 | 0.28% | ₹80.5 Cr |
Portfolios disclosed for Sep 2026. Weight is the holding as a share of the fund's assets.
Promoter and insider buying and selling
Trades made since 30 Oct 2025.Eris Lifesciences insider trading
No promoter, director, key manager or employee bought or sold on the market.
- Promoters and promoter group: no market trade · 13 pledge filings of unclear kind
- Others: no market trade · 2 pledge filings of unclear kind
Bought and sold count trades on the market only. A pledge is shares given to a lender as security for a loan; a lender invokes it by selling them.
Eris Lifesciences competitors and peers
Pharmaceuticals, 215 listed companies, priced on 30 Oct 2026. The table lists the 8 companies closest to Eris Lifesciences in market cap.Healthcare companies
Where the company sits among the companies nearest its size
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Caplin Point LaboratoriesCAPLIPOINT | 17,677 | 26.57 | 4.93 | +15.0% | +17.7% | 20.7% | 19.8% | 0.34% |
 Alivus Life SciencesALIVUS | 17,376 | 25.94 | 4.79 | +8.2% | +26.3% | 20.2% | 23.1% | 0.35% |
 Cohance LifesciencesCOHANCE | 16,999 | 160.02 | 4.35 | +41.2% | −58.5% | 3.8% | 3.0% | 0.00% |
 PfizerPFIZER | 16,871 | 22.95 | 4.01 | +10.7% | −9.1% | 17.5% | 21.0% | 2.03% |
 AstraZeneca Pharma IndiaASTRAZEN | 15,911 | 93.81 | 18.23 | +31.1% | −7.5% | 20.6% | 24.4% | 0.57% |
 Alembic PharmaceuticalsAPLLTD | 15,683 | 22.69 | 2.76 | +14.1% | +14.6% | 12.7% | 11.8% | 1.50% |
 Natco PharmaNATCOPHARM | 15,348 | 13.41 | – | −20.7% | −32.6% | 13.6% | 8.6% | 0.58% |
 Jubilant PharmovaJUBLPHARMA | 14,714 | 41.79 | 2.07 | +16.3% | −23.5% | 5.3% | 7.3% | 0.54% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Dividends
Per share, by the year it was paid for, and the latest payments.Eris Lifesciences dividend history
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up. Dividend per share in the glossaryHighest ₹7.35 a share, years to Mar 2023 and Mar 2025.
| Ex-date | Type | Per share |
|---|---|---|
| 29 May 2026 | Interim | ₹7.21 |
| 13 Feb 2025 | Interim | ₹7.35 |
| 11 Aug 2022 | Interim | ₹7.35 |
| 5 Aug 2021 | Interim | ₹6.01 |
| 13 Aug 2020 | Interim | ₹5.50 |
| 19 Mar 2020 | Interim | ₹2.87 |
Latest payments, as declared, by ex-date.
Latest announcements
Routine notices left out.Eris Lifesciences announcements
Oct 2026
29 Oct · Analysts
26 Oct · Results
19 Oct · Analysts
19 Oct · Board meeting
Sep 2026
Eris Lifesciences share price by year
Each calendar year to 2025.Eris Lifesciences share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 1,505.60 | +9.6% | 1,847.70 | 1,153.10 |
| 2024 | 1,373.70 | +51.0% | 1,522.70 | 831.30 |
| 2023 | 910.00 | +40.6% | 946.45 | 567.95 |
| 2022 | 647.25 | −14.8% | 764.35 | 621.70 |
| 2021 | 760.05 | +31.1% | 836.45 | 569.05 |
| 2020 | 579.95 | +22.4% | 595.15 | 362.15 |
| 2019 | 474.00 | −31.0% | 707.50 | 370.20 |
| 2018 | 687.15 | −13.5% | 826.10 | 589.35 |
| 2017 | 794.35 | – | 802.40 | 528.25 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. 2017 is from its first session, 29 Jun 2017.
Recent sessions
The 9 trading days to 29 Oct 2026, as traded on NSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 29 Oct 2026 | 1,170.20 | 1,183.50 | 1,155.50 | 1,163.60 | 1,171.81 | 29,738 | 45.0% |
| 28 Oct 2026 | 1,215.00 | 1,215.50 | 1,163.20 | 1,175.40 | 1,179.58 | 64,184 | 43.8% |
| 27 Oct 2026 | 1,134.90 | 1,215.00 | 1,120.40 | 1,198.40 | 1,182.44 | 7,42,044 | 38.8% |
| 26 Oct 2026 | 1,084.00 | 1,138.00 | 1,069.00 | 1,105.20 | 1,109.28 | 4,37,282 | 28.8% |
| 23 Oct 2026 | 1,126.60 | 1,126.60 | 1,087.90 | 1,095.50 | 1,102.67 | 37,943 | 48.8% |
| 22 Oct 2026 | 1,128.00 | 1,145.10 | 1,111.60 | 1,121.20 | 1,126.26 | 29,717 | 31.7% |
| 21 Oct 2026 | 1,120.40 | 1,149.90 | 1,112.90 | 1,136.30 | 1,133.71 | 84,960 | 47.4% |
| 19 Oct 2026 | 1,144.40 | 1,148.00 | 1,111.10 | 1,120.40 | 1,129.84 | 28,791 | 44.1% |
| 16 Oct 2026 | 1,144.00 | 1,155.90 | 1,130.60 | 1,144.40 | 1,145.59 | 80,705 | 81.2% |
Prices in ₹ per share as traded, not adjusted.
Company details
- NSE symbol
- ERIS
- BSE code
- 540596
- ISIN
- INE406M01024
- Industry
- Pharmaceuticals & Biotechnology
- Website
- www.eris.co.in
- CIN
- L24232GJ2007PLC049867
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 2007
- Registered office
- 8th floor, Commerce House IV, Beside Shall Petrol Pump, 100 Feet Road, Prahladnagar, Ahmedabad 380015, Gujarat
- Share registrar
- MUFG Intime India Pvt. Ltd
- Keeps the register of shareholders and handles transfers and dividend payments